(NASDAQ: ELVN) Enliven Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.01%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.56%.
Enliven Therapeutics's earnings in 2026 is -$105,927,000.On average, 16 Wall Street analysts forecast ELVN's earnings for 2026 to be -$138,782,148, with the lowest ELVN earnings forecast at -$147,200,959, and the highest ELVN earnings forecast at -$132,634,732. On average, 16 Wall Street analysts forecast ELVN's earnings for 2027 to be -$170,676,911, with the lowest ELVN earnings forecast at -$186,693,899, and the highest ELVN earnings forecast at -$148,483,197.
In 2028, ELVN is forecast to generate -$225,476,113 in earnings, with the lowest earnings forecast at -$274,296,421 and the highest earnings forecast at -$182,334,289.